The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.

We investigated the effectiveness of lamivudine to prevent hepatitis flare up due to reactivation of hepatitis-B virus (HBV) in hepatitis-B surface antigen (HBsAg)-positive patients with Non-Hodgkin's lymphoma (NHL) during cytotoxic chemotherapy. HBsAg-positive patients with NHL were identified...

Full description

Bibliographic Details
Main Authors: Lee, Gyeong-Won, Ryu, Min-Hee, Lee, Jae-Lyun, Oh, Sukjoong, Kim, Eunkyoung, Lee, Jae-Hwan, Kim, Seung-Bae, Kim, Sang-We, Suh, Cheolwon, Lee, Kyoo-Hyung, Kim, Woo-Kun, Lee, Jung-Shin, Kang, Yoon-Koo
Format: Online
Language:English
Published: Korean Academy of Medical Sciences 2003
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055150/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055150/

Similar Items